Skip to main content
Top
Published in: International Journal of Hematology 6/2018

01-12-2018 | Original Article

Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study

Authors: Andrea Piccin, Mario Tagnin, Cinzia Vecchiato, Ahmad Al-Khaffaf, Lisa Beqiri, Caroline Kaiser, Iris Agreiter, Giovanni Negri, Michael Kob, Angela Di Pierro, Fabio Vittadello, Guido Mazzoleni, Klaus Eisendle, Fabrizio Fontanella

Published in: International Journal of Hematology | Issue 6/2018

Login to get access

Abstract

Graft-versus-host disease (GvHD) causes severe mucositis, impairs feeding and favors infection. The objective of this study was to identify the impact of GvHD in the oral cavity. We reviewed all consecutive patients who developed oral GvHD after HSCT. The study period was over 14 years. 53 patients were identified. M/F = 1.4; median age was 48.6 years; the median follow-up was for up to 3 years and 6 months. Conditioning regimens included several drugs (e.g., busulfan, cyclophosphamide and fludarabine). In 11 cases, radiotherapy (RT) was also used. Patients treated with RT were more likely to have tooth decay requiring fillings (p = 0.029), to need canal root interventions (p = 0.005) and to have tartar requiring oral hygiene interventions (p = 0.011). Patients with a lymphoma diagnosis were more likely to develop perioral scleroderma and chronic oral GvHD (cGvHD) (p = 0.045). Oral acute GvHD (aGvHD) was seen in 26 patients (49.1%). 21 (39.6%) patients developed cGvHD. GvHD of the tongue was seen in 21 (40%) patients. Oral mucositis was seen in only 5 patients (9.4%). Conditioning regimens with RT are more likely to induce oral aGvHD. The tongue is often affected by GvHD.
Literature
1.
go back to reference Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Hematology / the Education Program of the American Society of Hematology. 2012, pp. 251–64. Pavletic SZ, Fowler DH. Are we making progress in GVHD prophylaxis and treatment? Hematology / the Education Program of the American Society of Hematology. 2012, pp. 251–64.
2.
go back to reference Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;6:443–58.CrossRef Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;6:443–58.CrossRef
3.
go back to reference Gräf Saffig M, Klinikleitfaden. München: Urban & Fischer. 2012. Gräf Saffig M, Klinikleitfaden. München: Urban & Fischer. 2012.
4.
go back to reference Petersdorf E, Anasetti C, Servida P, Martin P, Hansen J. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;1:107–21.CrossRef Petersdorf E, Anasetti C, Servida P, Martin P, Hansen J. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998;1:107–21.CrossRef
5.
go back to reference Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;17:1813–26.CrossRef Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;17:1813–26.CrossRef
6.
go back to reference Travnik R, Beckers M, Wolff D, Holler E, Landthaler M, Karrer S. Graft-versus-Host Disease (GvHD) - an update: Part 1: Pathophysiology, clinical features and classification of GvHD. Hautarzt. 2011;2:139–54.CrossRef Travnik R, Beckers M, Wolff D, Holler E, Landthaler M, Karrer S. Graft-versus-Host Disease (GvHD) - an update: Part 1: Pathophysiology, clinical features and classification of GvHD. Hautarzt. 2011;2:139–54.CrossRef
7.
go back to reference Ruutu T, Hermans J, van Biezen A, Niederwieser D, Gratwohl A, Apperley JF. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1998;6:614–5.CrossRef Ruutu T, Hermans J, van Biezen A, Niederwieser D, Gratwohl A, Apperley JF. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1998;6:614–5.CrossRef
8.
go back to reference Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;4:327–46.CrossRef Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW. Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis. 2013;4:327–46.CrossRef
9.
go back to reference Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood. 2012;17:3407–18.CrossRef Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood. 2012;17:3407–18.CrossRef
10.
go back to reference Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;1:79–109.CrossRef Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;1:79–109.CrossRef
11.
go back to reference Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G, et al. Platelet gel: a new therapeutic tool with great potential. Blood Transfus. 2017;4:333–40. Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G, et al. Platelet gel: a new therapeutic tool with great potential. Blood Transfus. 2017;4:333–40.
12.
go back to reference Piccin A, Di Pierro AM, Tagnin M, Russo C, Fustos R, Corvetta D, et al. Healing of a soft tissue wound of the neck and jaw osteoradionecrosis using platelet gel. Regen Med. 2016;5:459–63.CrossRef Piccin A, Di Pierro AM, Tagnin M, Russo C, Fustos R, Corvetta D, et al. Healing of a soft tissue wound of the neck and jaw osteoradionecrosis using platelet gel. Regen Med. 2016;5:459–63.CrossRef
13.
go back to reference Piccin A, Di Pierro AM, Corvetta D, Canzian L, Gentilini I, Primerano M, et al. Severe skin radiodermatitis fully healed with the use of platelet gel and a hyperbaric chamber. Blood Transfus. 2015;6:552–4. Piccin A, Di Pierro AM, Corvetta D, Canzian L, Gentilini I, Primerano M, et al. Severe skin radiodermatitis fully healed with the use of platelet gel and a hyperbaric chamber. Blood Transfus. 2015;6:552–4.
14.
go back to reference Piccin A, Rebulla P, Pupella S, Tagnin M, Marano G, Di Pierro AM, et al. Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel. Transfusion. 2017;9:2220–4.CrossRef Piccin A, Rebulla P, Pupella S, Tagnin M, Marano G, Di Pierro AM, et al. Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel. Transfusion. 2017;9:2220–4.CrossRef
15.
go back to reference Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;13:897–904.CrossRef Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;13:897–904.CrossRef
16.
go back to reference Jacobsohn DA. Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs. 2002;9:1271–80.CrossRef Jacobsohn DA. Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs. 2002;9:1271–80.CrossRef
17.
go back to reference Bassim CW, Fassil H, Dobbin M, Steinberg SM, Baird K, Cole K, et al. Malnutrition in patients with chronic GVHD. Bone Marrow Transpl. 2014;10:1300–6.CrossRef Bassim CW, Fassil H, Dobbin M, Steinberg SM, Baird K, Cole K, et al. Malnutrition in patients with chronic GVHD. Bone Marrow Transpl. 2014;10:1300–6.CrossRef
18.
go back to reference Browning B, Thormann K, Seshadri R, Duerst R, Kletzel M, Jacobsohn DA. Weight loss and reduced body mass index: a critical issue in children with multiorgan chronic graft-versus-host disease. Bone Marrow Transpl. 2006;5:527–33.CrossRef Browning B, Thormann K, Seshadri R, Duerst R, Kletzel M, Jacobsohn DA. Weight loss and reduced body mass index: a critical issue in children with multiorgan chronic graft-versus-host disease. Bone Marrow Transpl. 2006;5:527–33.CrossRef
19.
go back to reference Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB. Weight loss and malnutrition in patients with chronic graft-versus-host disease. Bone Marrow Transpl. 2006;5:527–33. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB. Weight loss and malnutrition in patients with chronic graft-versus-host disease. Bone Marrow Transpl. 2006;5:527–33.
20.
go back to reference Zauner C, Rabitsch W, Schneeweiss B, Schiefermeier M, Greinix HT, Ratheiser K, et al. Energy and substrate metabolism in patients with chronic extensive graft-versus-host disease. Transplantation. 2001;4:524–8.CrossRef Zauner C, Rabitsch W, Schneeweiss B, Schiefermeier M, Greinix HT, Ratheiser K, et al. Energy and substrate metabolism in patients with chronic extensive graft-versus-host disease. Transplantation. 2001;4:524–8.CrossRef
21.
go back to reference Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.CrossRef Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.CrossRef
22.
go back to reference Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transpl. 2006;4:375–96.CrossRef Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease:V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transpl. 2006;4:375–96.CrossRef
23.
go back to reference Bystricka E, Ghelase R, Gorican IK, Mazur E, Vokurka S, East Forum EBMT Nurses Group. Oral cavity care in patients after high-dose chemotherapy and stem cell transplantation: the East Forum EBMT Nurses Group standard of care. Bone Marrow Transpl. 2012;1:149–50.CrossRef Bystricka E, Ghelase R, Gorican IK, Mazur E, Vokurka S, East Forum EBMT Nurses Group. Oral cavity care in patients after high-dose chemotherapy and stem cell transplantation: the East Forum EBMT Nurses Group standard of care. Bone Marrow Transpl. 2012;1:149–50.CrossRef
24.
25.
go back to reference Wagner JL, Flowers ME, Longton G, Storb R, Schubert M, Sullivan KM. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transpl. 1998;2:139–46.CrossRef Wagner JL, Flowers ME, Longton G, Storb R, Schubert M, Sullivan KM. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Bone Marrow Transpl. 1998;2:139–46.CrossRef
26.
go back to reference Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2006;2:138–51.CrossRef Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2006;2:138–51.CrossRef
27.
go back to reference Dahllöf G, Modéer T, Bolme P, Ringdén O, Heimdahl A. Oral health in children treated with bone marrow transplantation: a one-year follow-up. ASDC J Dent Child. 1988;3:196–200. Dahllöf G, Modéer T, Bolme P, Ringdén O, Heimdahl A. Oral health in children treated with bone marrow transplantation: a one-year follow-up. ASDC J Dent Child. 1988;3:196–200.
28.
go back to reference Heimdahl A, Johnson G, Danielsson KH, Lönqvist B, Sundelin P, Ringden O. Oral condition of patients with leukemia and severe aplastic anemia. Follow-up 1 year after bone marrow transplantation. 5. Oral Medicine: Oral Surgery; 1985. pp. 498–504. Heimdahl A, Johnson G, Danielsson KH, Lönqvist B, Sundelin P, Ringden O. Oral condition of patients with leukemia and severe aplastic anemia. Follow-up 1 year after bone marrow transplantation. 5. Oral Medicine: Oral Surgery; 1985. pp. 498–504.
29.
go back to reference Liśniewska-Machorowska B, Ksiazek-Bak H, Pisulska-Otremba A. Assessment of the condition of the parodontium in children undergoing maxillary-orthopaedic treatment with reference to malocclusion, groups of teeth and duration of treatment with orthodontic devices. Czas Stomatol. 1990;9:567–72. Liśniewska-Machorowska B, Ksiazek-Bak H, Pisulska-Otremba A. Assessment of the condition of the parodontium in children undergoing maxillary-orthopaedic treatment with reference to malocclusion, groups of teeth and duration of treatment with orthodontic devices. Czas Stomatol. 1990;9:567–72.
30.
go back to reference Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H, et al. Oral chronic graft-versus-host disease: report from the international consensus conference on clinical practice in cGVHD. Clin oral investing. 2011; 2:127–39.CrossRef Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H, et al. Oral chronic graft-versus-host disease: report from the international consensus conference on clinical practice in cGVHD. Clin oral investing. 2011; 2:127–39.CrossRef
31.
go back to reference Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2012;10:1573–9.CrossRef Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2012;10:1573–9.CrossRef
32.
go back to reference Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;9677:1798–807.CrossRef Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet. 2009;9677:1798–807.CrossRef
33.
go back to reference Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. ESPEN. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr. 2009;4:445–54.CrossRef Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. ESPEN. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr. 2009;4:445–54.CrossRef
Metadata
Title
Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study
Authors
Andrea Piccin
Mario Tagnin
Cinzia Vecchiato
Ahmad Al-Khaffaf
Lisa Beqiri
Caroline Kaiser
Iris Agreiter
Giovanni Negri
Michael Kob
Angela Di Pierro
Fabio Vittadello
Guido Mazzoleni
Klaus Eisendle
Fabrizio Fontanella
Publication date
01-12-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2520-5

Other articles of this Issue 6/2018

International Journal of Hematology 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine